TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Wuxi Biologics (Cayman) ( (HK:2269) ) has shared an announcement.
Wuxi Biologics reported strong financial performance for the first half of 2025, with a 16.1% increase in revenue and a 54.8% rise in net profit compared to the previous year. The company secured 86 new integrated projects, bringing its total to 864, and demonstrated robust growth in both pre-clinical and commercial manufacturing projects, highlighting its sustainable development capabilities.
The most recent analyst rating on (HK:2269) stock is a Buy with a HK$36.00 price target. To see the full list of analyst forecasts on Wuxi Biologics (Cayman) stock, see the HK:2269 Stock Forecast page.
More about Wuxi Biologics (Cayman)
Wuxi Biologics (Cayman) Inc. operates in the biotechnology industry, focusing on providing comprehensive contract research, development, and manufacturing services (CRDMO) for biologics. The company emphasizes its ‘Follow and Win the Molecule’ strategies to secure and expand its project portfolio.
Average Trading Volume: 50,506,397
Technical Sentiment Signal: Buy
Current Market Cap: HK$125.9B
For detailed information about 2269 stock, go to TipRanks’ Stock Analysis page.